Article
17 Jan 2025
Year In Review: Top Legal Developments Of 2024
RANKINGS
This author falls within the Top 20% for their listed topics and industry categories. Based on Mondaq users readership, this author is ranked as VERY POPULAR in United States
AUTHORS CONTENT
Article
14 May 2024
IRA Litigation Updates: D.N.J. Rejects Challenges From BMS And Janssen; Four Cases Now On Appeal
Article
11 Mar 2024
Court Grants Summary Judgment Ending AstraZeneca's Lawsuit Challenging The IRA
Article
20 Feb 2024
Court Dismisses PhRMA Lawsuit Challenging IRA
Article
16 Jan 2024
Goodwin Releases Update To Its Comprehensive Guide To Biosimilars Litigation And Regulation In The U.S.
Article
09 Nov 2023
FDA Approves Amgen's WEZLANA As Biosimilar To And Interchangeable With Janssen's STELARA (Ustekinumab) – Stelara Is One Of The 10 Drugs Selected By CMS For Drug Price Negotiations Under The Inflation Reduction Act
Article
20 Oct 2023
Recent FDA Initiatives To Support Development Of Individualized Cell And Gene Therapies And Rare Disease Therapies
Article
03 Oct 2023
IRA Drug Price Negotiation Program Litigation Updates – Denial Of PI Motion And Motion To Dismiss In Chambers Of Commerce Case And New Complaint Filed By Novo Nordisk
Article
01 Sep 2023
BREAKING NEWS – HHS Announces The First 10 Drugs Selected For IRA Drug Price Negotiation Program